Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Accured Expenses (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Accured Expenses for 16 consecutive years, with -$3.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 127.08% to -$3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.0 million, a 54.74% increase, with the full-year FY2022 number at $1.9 million, up 152.01% from a year prior.
  • Change in Accured Expenses was -$3.5 million for Q3 2025 at Gyre Therapeutics, down from -$2.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.2 million in Q4 2022 to a low of -$5.2 million in Q4 2021.
  • A 5-year average of -$401823.5 and a median of -$70000.0 in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 3441.94% in 2022, then tumbled 3275.71% in 2025.
  • Gyre Therapeutics' Change in Accured Expenses stood at -$5.2 million in 2021, then surged by 220.92% to $6.2 million in 2022, then plummeted by 148.18% to -$3.0 million in 2023, then skyrocketed by 48.47% to -$1.5 million in 2024, then plummeted by 127.08% to -$3.5 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Accured Expenses are -$3.5 million (Q3 2025), -$2.4 million (Q2 2025), and $4.4 million (Q1 2025).